Novartis’s Beovu Gets EU Approval as Blindness Treatment

- Advertisement -


By Joshua Kirby
- Advertisement -

Novartis AG said Thursday that the European Union has approved its drug Beovu as a treatment for blindness in people living with diabetic macular edema, or DME.

- Advertisement -

The approval by the bloc’s executive arm, the European Commission, follows successful Phase 3 study data that met a primary endpoint of non-inferiority in change in best-corrected visual acuity from baseline versus aflibercept at year one, the Swiss drug maker said.

The decision means Beovu will be available as a treatment for DME, a leading cause of blindness among adults in developed countries, across the EU and in Iceland, Liechtenstein and Norway, the company said.

- Advertisement -

The approval is the second granted to Beovu, which the EC in 2020 approved as a treatment for wet age-related macular degeneration, Novartis said.

Beovu remains under review for approval in the US and Japan, Novartis said.

Write to Joshua Kirby at [email protected]; @joshualeokirby

,

Credit: www.marketwatch.com /

- Advertisement -

Stay on top - Get the daily news in your inbox

DMCA / Correction Notice

Recent Articles

Related Stories

Stay on top - Get the daily news in your inbox